Table 2 Primary and secondary outcomes after PSM
Variable | Dexmedetomidine group | Control group | 95% CI | P Value |
|---|---|---|---|---|
Blood loss (mL), mean ± SD | 670.83 ± 273.23 | 732.31 ± 286.88 | − 94.93 to − 28.03 |  < 0.001 |
Postoperative haemoglobin (g/L), mean ± SD | 103.92 ± 14.60 | 100.23 ± 16.18 | 1.72 to 5.66 |  < 0.001 |
Intraoperative HR (bpm), mean ± SD | ||||
 T1 | 70.89 ± 11.05 | 78.06 ± 13.10 | − 8.62 to − 5.73 |  < 0.001 |
 T2 | 72.93 ± 11.28 | 79.72 ± 11.58 | − 8.15 to − 5.42 |  < 0.001 |
 T3 | 71.87 ± 10.38 | 79.66 ± 11.29 | − 9.09 to − 6.50 |  < 0.001 |
 T4 | 69.79 ± 10.54 | 78.40 ± 10.67 | − 9.88 to − 7.34 |  < 0.001 |
Intraoperative BP (mmHg), mean ± SD | ||||
 T1 | 60.22 ± 9.99 | 62.50 ± 10.48 | − 3.50 to − 1.06 |  < 0.001 |
 T2 | 55.94 ± 7.69 | 56.74 ± 8.89 | − 1.80 to 0.18 | 0.112 |
 T3 | 54.74 ± 5.89 | 54.90 ± 7.05 | − 0.94 to 0.60 | 0.673 |
 T4 | 56.19 ± 7.92 | 57.02 ± 8.92 | − 1.84 to 0.18 | 0.109 |
Operation time (h), mean ± SD | 3.57 ± 1.12 | 3.62 ± 1.22 | − 0.19 to 0.09 | 0.499 |
Fentanyl (mg), mean ± SD | 0.35 ± 0.07 | 0.35 ± 0.07 | − 0.01 to 0.01 | 0.881 |
Remifentanil (mg), mean ± SD | 1.23 ± 0.45 | 1.49 ± 0.61 | − 0.32 to − 0.19 |  < 0.001 |
Incidence of allogeneic blood transfusion (transfused /not transfused) | 32/508 | 35/505 | / | 0.801 |
Urapidil (mg), mean ± SD | 12.60 ± 5.88 | 12.41 ± 5.48 | − 0.48 to 0.87 | 0.574 |
Esmolol (mg), mean ± SD | 18.04 ± 10.02 | 25.37 ± 10.88 | − 8.58 to − 6.08 |  < 0.001 |